Novo Nordisk A/S (NVO)

138.07
+1.28(+0.94%)
Pre Market
138.90
+0.83(+0.60%)
- Real-time Data
  • Volume:
    1,681,905
  • Day's Range:
    136.96 - 138.83
  • 52 wk Range:
    94.75 - 157.87

NVO Overview

Prev. Close
136.79
Day's Range
136.96-138.83
Revenue
176.95B
Open
137.62
52 wk Range
94.75-157.87
EPS
24.51
Volume
1,681,905
Market Cap
313.21B
Dividend (Yield)
1.2595
(0.91%)
Average Vol. (3m)
1,443,695
P/E Ratio
39.33
Beta
0.355
1-Year Change
38.53%
Shares Outstanding
2,258,087,613
Next Earnings Date
May 04, 2023
What is your sentiment on Novo Nordisk ADR?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S News

Novo Nordisk A/S Analysis

Novo Nordisk A/S Company Profile

Novo Nordisk A/S Company Profile

Industry
-
Sector
-
Employees
54789

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Read More

Analyst Price Target

Average1,010.89 (+632.16% Upside)
High1,093.00
Low855.816
Price138.07
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong SellSellStrong BuySellStrong Buy
SummaryNeutralNeutralStrong BuyNeutralStrong Buy
  • Bright future for this company
    0
    • ONE DAY THESE GUYS WILL CURE DIABETES
      0
      • NVO offers great products. I'm long term here!!!!
        0
        • Their weight loss drug is getting massive attention on social media. this is helping Novo Nordisk to sell all they can make. This stock is a major buy
          0
          • novo very expensive drug market hemophilia drug big profitible business
            0
            • Novo Nordisk announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
              0
              • I'm in the middle off it (working at NN). Massive undertaking and people are rushing to this company. 30% up last year and 33% this year up the hiring
                0
            • sure, best company
              0
              • NVO WILL BUY ORMP AT 30 $
                1
                • and Gals..! :D
                  0
                  • Guys, think about this and USA market...and market all around the world. The same Type 2 diabetes drug semaglutide seems to work well against obesity.  This can be a massive hit! https://www.fiercepharma.com/pharma/novo-nordisk-makes-headway-bid-to-rule-obesity-market-stunning-phase-3-semaglutide-data
                    1
                    • Seems that the importance of these results is being overlooked at the moment for some strange reason.  Might be a good idea to stay in long.
                      0
                    • Could be massive?? It will be now approved by FDA in US and soon EU all that remains is production cabability which was surprisingly not ready for such a demand (only US) so IMO this WILL exploded 10 fold what NN has expected., maybe more. Where do you find a obesity drug that helps? What obesity formulars has ever worked? This actually dos work.. Get ready!!!
                      0